Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation

• Published in: Clinical gastroenterology and hepatology Vol. 13; no. 2; pp. 294 - 301.e5
• Main Authors: Fukudo, Shin, Hongo, Michio, Kaneko, Hiroshi, Takano, Masahiro, Ueno, Ryuji
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2015
• Subjects: Adult; Aged; Aged, 80 and over; Constipation - drug therapy; Double-Blind Method; Female; Functional Disorder; Gastroenterology and Hepatology; Gastrointestinal Agents - administration & dosage; Gastrointestinal Motility - drug effects; Humans; IBS; Intestine; Intestines - drug effects; Intestines - physiology; Japan; Lubiprostone - administration & dosage; Male; Middle Aged; Placebos - administration & dosage; QOL; Quality of Life; Rome III Criteria; Small-Bowel Transit; Treatment Outcome; Young Adult; Japan; SES; GI; Rome III Criteria; Functional Disorder; QOL; SF-36; IBS-C; Intestine; Small-Bowel Transit; FAS; IBS; CIC; SBM; irritable bowel syndrome with constipation; chronic idiopathic constipation; irritable bowel syndrome; full-analysis set; gastrointestinal; safety-evaluable set; spontaneous bowel movement; Short-Form Health Survey Questionnaire; quality of life

Lubiprostone is an activator of the type 2 chloride channel that facilitates spontaneous bowel movement (SBM). We performed phase 3 studies to determine whether lubiprostone increases the frequency of SBM in patients with chronic idiopathic constipation (CIC) in Japan, and whether long-term administ...